Somatic BRCA2 loss-of-function in HER2-neg metastatic breast: TBCRC-048 demonstrated tala...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA2-SOMATIC-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BRCA2 somatic loss-of-function |
| Disease | DIS-BREAST |
| ESCAT tier | IB |
| Recommended combinations | talazoparib monotherapy (off-label), olaparib monotherapy (off-label) |
| Evidence summary | Somatic BRCA2 loss-of-function in HER2-neg metastatic breast: TBCRC-048 demonstrated talazoparib activity (ORR ~31%); PARPi labels in breast remain germline-only. ESCAT IB / OncoKB Level 2. |
Notes
Reflex germline testing recommended.
Used By
No reverse references found in the YAML corpus.